LifeFactFuture project offers fresh insights and innovative solutions to Revvity
Us at Revvity chose to join the LifeFactFuture (LFF) consortium to gain fresh insights and innovative solutions from our industry peers, while also providing a robust platform for advancing academic research. At Revvity, we are dedicated to addressing the world’s most challenging health issues by developing cutting-edge solutions that enhance precision, streamline complexity, and accelerate the journey from discovery to cure. At our Turku Site, we are particularly passionate about advancing the health and well-being of pregnant women and newborns. Our operations here are heavily focused on the manufacturing of instruments and reagents specifically designed for prenatal and newborn screening. This specialization allows us to contribute significantly to early detection, which is crucial for ensuring a healthy beginning for each.
Embracing Digitalization for Efficiency and Innovation
The primary goal of our digitalization project at the Turku Site is to enhance the efficiency of our manufacturing processes. By integrating advanced digital solutions, we aim to discover innovative ways to optimize our operations. This not only improves productivity but also ensures that we remain at the forefront of technological advancements in the healthcare industry. One of the most exciting aspects of this project for us is the development of electronic instructions for use with all our products, which streamlines the user experience and ensures that our customers have access to the most up-to-date information.
The LFF consortium brings together world-class excellence from Finnish life science companies, technology companies, and academic researchers, including teams from the University of Turku and the University of Helsinki. This collaboration aims to enhance advanced pharmaceutical and life science manufacturing in Finland by integrating data-driven capabilities and digital solutions. By participating in this consortium, we are not only contributing to cutting-edge research but also helping to position Finland as a global leader in life science manufacturing.
Commitment to Quality, Patient Safety, and Sustainability
Quality and patient safety are our top priorities. The reagents and instruments produced at the Revvity Turku Site are IVD (In Vitro Diagnostic) grade medical devices. This means they meet the highest standards of quality and safety, essential for accurate and reliable diagnostic testing. We are also committed to innovation in managing country-specific regulatory requirements, ensuring that our products comply with diverse international standards. Digitalization is key with controlling all the different requirements.
In addition to our focus on quality and safety, we are deeply committed to sustainability. Our manufacturing processes are designed to minimize environmental impact, and we continuously seek ways to reduce waste and energy consumption. By prioritizing eco-friendly practices, we aim to contribute to a healthier planet while delivering top-notch healthcare solutions. For example the electronic instructions for use will reduce our paper usage drastically.
Our Vision for the Future
Looking ahead, we envision a future where our innovative solutions continue to make a profound impact on global health. By staying true to our mission and continuously pushing the boundaries of what is possible, we strive to create a world where advanced health science is within reach for all, leading to better health outcomes and improved quality of life.
Peppi Pietarinen
Senior Operations Manager, Revvity
– – –
Picture: The second consortium meeting took place at Revvity on 4 October 2024.
Photos taken by Juuso Korsimo.